liu.seSearch for publications in DiVA
Change search
Refine search result
1 - 5 of 5
CiteExportLink to result list
Permanent link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Rows per page
  • 5
  • 10
  • 20
  • 50
  • 100
  • 250
Sort
  • Standard (Relevance)
  • Author A-Ö
  • Author Ö-A
  • Title A-Ö
  • Title Ö-A
  • Publication type A-Ö
  • Publication type Ö-A
  • Issued (Oldest first)
  • Issued (Newest first)
  • Created (Oldest first)
  • Created (Newest first)
  • Last updated (Oldest first)
  • Last updated (Newest first)
  • Disputation date (earliest first)
  • Disputation date (latest first)
  • Standard (Relevance)
  • Author A-Ö
  • Author Ö-A
  • Title A-Ö
  • Title Ö-A
  • Publication type A-Ö
  • Publication type Ö-A
  • Issued (Oldest first)
  • Issued (Newest first)
  • Created (Oldest first)
  • Created (Newest first)
  • Last updated (Oldest first)
  • Last updated (Newest first)
  • Disputation date (earliest first)
  • Disputation date (latest first)
Select
The maximal number of hits you can export is 250. When you want to export more records please use the Create feeds function.
  • 1.
    Blomqvist, Henrik
    Linköping University, Department of Medicine and Care, Internal Medicine. Linköping University, Faculty of Health Sciences.
    Monocyte chemoattractant protein-1 and CC-chemokine receptor-2 in two different conditions related to atherosclerosis2004Licentiate thesis, comprehensive summary (Other academic)
    Abstract [en]

    Atherosclerosis is the leading cause of death in the industrialized parts of the world. The pathological process is characterised by increased lipid influx to the arterial wall due to elevated circulating levels of low density lipoprotein (LDL). LDL is oxidatively modified by reactive oxygen species forming oxLDL. OxLDL is highly proinflammatory and is initiating an inflammatory response in the artery by up-regulation of proinflammatory signals e.g. Monocyte chemoattractant protein-1 (MCP-1). MCP-1 is promoting monocyte arrest on the endothelium and subsequent transmigration to the intima. MCP-1 is acting through the CC-chemokine receptor-2 (CCR2) on monocytes. MCP-1 and CCR2 are playing key-roles in atherogenesis through their effect on monocyte recruitment. In this thesis MCP-1 and CCR2 were studied in two clinically different conditions related to atherosclerosis - isolated asymptomatic hypercholesterolaemia and diagnosed coronary artery disease (CAD). We wanted to study the possible differences of proatherogenic patterns in clinical conditions that are at opposite ends in the clinical spectrum of atherosclerosis.

    In paper I, we studied if plasma levels of MCP-1 and the gene expression of CCR-2 were elevated above normal in subjects with asymptomatic, isolated hypercholesterolaemia and if statin treatment could influence plasma levels of MCP-1 and other inflammatory markers. In paper ll we studied the same parameters but in patients with diagnosed CAD as stable angina pectoris and acute coronary syndrome. In neither study we could see any differences regarding MCP-1 or CCR2 between patients and controls. However, in the CAD patients we could see an increased inflammatory activity as elevated levels of CRP. This inflammatory activity was not reflected on any other of the inflammatory markers analysed. In conclusion, the results from this thesis do not support the idea of circulating MCP-1 and CCR2 gene expression on circulating monocytes as clinical markers of atherosclerosis in these patient categories.

    List of papers
    1. Monocyte chemoattractant protein‐1 and CC‐chemokine receptor‐2 in severe hypercholesterolaemia
    Open this publication in new window or tab >>Monocyte chemoattractant protein‐1 and CC‐chemokine receptor‐2 in severe hypercholesterolaemia
    2003 (English)In: Scandinavian Journal of Clinical and Laboratory Investigation, ISSN 0036-5513, E-ISSN 1502-7686, Vol. 63, no 7-8, p. 513-519Article in journal (Refereed) Published
    Abstract [en]

    Objectives: To investigate whether plasma concentrations of monocyte chemoattractant protein‐1 (MCP‐1) and the gene expression of its receptor on the monocyte cell surface CCR‐2 were elevated above normal in subjects with asymptomatic, isolated hypercholesterolaemia and if statin treatment could influence this cytokine.

    Methods: The investigation was designed as a cross sectional study followed by a single, blind, treatment study of patients receiving pravastatin 80 mg/day for 8 weeks. The study included 23 patients with severe hypercholesterolaemia (LDL>5.2 mmol/L) and 39 normocholesterolaemic controls. Blood samples were obtained from patients and controls at baseline and from patients at end of the study and analysed for lipoproteins and inflammatory mediators: MCP‐1, high‐sensitivity C‐reactive protein (HS‐CRP). Isolated peripheral mononuclear cells were analysed for CCR‐2 gene expression.

    Results: Mean plasma LDL‐C was significantly higher in patients than in controls. No difference in plasma MCP‐1 levels or CCR‐2 gene expression was seen between the groups at baseline, nor were there any differences in plasma concentrations of CRP. After treatment with pravastatin, LDL‐C decreased by 31%. Treatment did not significantly affect the levels of MCP‐1 or CCR‐2 gene expression, nor was CRP affected by treatment with pravastatin.

    Conclusions: Our study does not support the view that MCP‐1 plasma levels and CCR‐2 gene expression in circulating monocytes are directly responsible for the monocyte recruitment into the arterial intima in patients with severe asymptomatic hypercholesterolaemia. In addition, the inflammatory response of a high concentration of LDL‐C in isolated asymptomatic hypercholesterolaemia is minute.

    Keywords
    CC‐chemokine receptor‐2, C‐reactive protein, hypercholesterolaemia, inflammation, monocyte chemoattractant protein‐1, pravastatin
    National Category
    Medical and Health Sciences
    Identifiers
    urn:nbn:se:liu:diva-26817 (URN)10.1080/00365510310003274 (DOI)000187774200008 ()11429 (Local ID)11429 (Archive number)11429 (OAI)
    Available from: 2009-10-08 Created: 2009-10-08 Last updated: 2017-12-13
    2. Monocyte chemoattractant protein‐1 and CC‐chemokine receptor‐2 in coronary artery disease
    Open this publication in new window or tab >>Monocyte chemoattractant protein‐1 and CC‐chemokine receptor‐2 in coronary artery disease
    (English)Manuscript (preprint) (Other academic)
    Abstract [en]

    Objectives: To investigate the expression of monocyte chemoattractant protein-1 (MCP-1) and CC chemokine receptor-2 (CCR-2) in circulating monocytes in patients with stable (SAP) and acute coronary syndrome (ACS), and relate the findings to circulating levels of MCP-1 and other inflammatory biomarkers.

    Methods: The study included 40 patients each with stable CAD and unstable CAD, and a control group of 50 age- and sex-matched healthy persons. Whole blood was taken and sera were analyzed for MCP-1, IL-6, sVCAM-1, siCAM-1 and P-selectin using ELISA and CRP was analysed by Tina-quant CRP high sensitive assay. Monocytes were isolated from whole blood and were analyzed for CCR-2 and MCP-1 gene expression using realtime RT-PCR.

    Results: No significant differences in gene expression of MCP-1 or CCR-2 were seen between the groups. Neither were any differences in circulating levels of MCP-1-seen. Serum levels of sVCAM-1, siCAM-1 and sP-selectin did not differ between the groups. Mean CRP levels were elevated in the ACS group compared to controls and SAP. Patients with SAP had lower levels compared to controls, probably reflecting the extensive use of statins in this group (96 %). IL-6 was significantly higher in ACS compared to controls and SAP. Positive correlations were seen between MCP-1 vs. sVCAM-1 and sICAM-1.

    Conclusions: Neither patients with SAP nor ACS had different MCP-1 or CCR-2 gene expression compared to controls. The serum levels of MCP-1 did not differ between the groups. In this study, we can not see circulating MCP-1 or CCR-2 gene expression in monocytes as useful clinical tools to decide the severity of CAD in this population.

    National Category
    Medical and Health Sciences
    Identifiers
    urn:nbn:se:liu:diva-97349 (URN)
    Available from: 2013-09-10 Created: 2013-09-10 Last updated: 2013-09-10
  • 2.
    Blomqvist, Henrik
    et al.
    Linköping University, Department of Medicine and Care, Internal Medicine. Linköping University, Faculty of Health Sciences.
    Jonasson, L.
    Linköping University, Department of Medicine and Care. Linköping University, Faculty of Health Sciences.
    Olsson, A.
    Linköping University, Department of Medicine and Care, Internal Medicine. Linköping University, Faculty of Health Sciences.
    Monocyte chemoattractant protein‐1 and CC‐chemokine receptor‐2 in coronary artery diseaseManuscript (preprint) (Other academic)
    Abstract [en]

    Objectives: To investigate the expression of monocyte chemoattractant protein-1 (MCP-1) and CC chemokine receptor-2 (CCR-2) in circulating monocytes in patients with stable (SAP) and acute coronary syndrome (ACS), and relate the findings to circulating levels of MCP-1 and other inflammatory biomarkers.

    Methods: The study included 40 patients each with stable CAD and unstable CAD, and a control group of 50 age- and sex-matched healthy persons. Whole blood was taken and sera were analyzed for MCP-1, IL-6, sVCAM-1, siCAM-1 and P-selectin using ELISA and CRP was analysed by Tina-quant CRP high sensitive assay. Monocytes were isolated from whole blood and were analyzed for CCR-2 and MCP-1 gene expression using realtime RT-PCR.

    Results: No significant differences in gene expression of MCP-1 or CCR-2 were seen between the groups. Neither were any differences in circulating levels of MCP-1-seen. Serum levels of sVCAM-1, siCAM-1 and sP-selectin did not differ between the groups. Mean CRP levels were elevated in the ACS group compared to controls and SAP. Patients with SAP had lower levels compared to controls, probably reflecting the extensive use of statins in this group (96 %). IL-6 was significantly higher in ACS compared to controls and SAP. Positive correlations were seen between MCP-1 vs. sVCAM-1 and sICAM-1.

    Conclusions: Neither patients with SAP nor ACS had different MCP-1 or CCR-2 gene expression compared to controls. The serum levels of MCP-1 did not differ between the groups. In this study, we can not see circulating MCP-1 or CCR-2 gene expression in monocytes as useful clinical tools to decide the severity of CAD in this population.

  • 3.
    Blomqvist, Henrik
    et al.
    Linköping University, Department of Medicine and Care, Internal Medicine. Linköping University, Faculty of Health Sciences.
    Olsson, Anders
    Linköping University, Department of Medicine and Care, Internal Medicine. Linköping University, Faculty of Health Sciences.
    Monocyte chemoattractant protein‐1 and CC‐chemokine receptor‐2 in severe hypercholesterolaemia2003In: Scandinavian Journal of Clinical and Laboratory Investigation, ISSN 0036-5513, E-ISSN 1502-7686, Vol. 63, no 7-8, p. 513-519Article in journal (Refereed)
    Abstract [en]

    Objectives: To investigate whether plasma concentrations of monocyte chemoattractant protein‐1 (MCP‐1) and the gene expression of its receptor on the monocyte cell surface CCR‐2 were elevated above normal in subjects with asymptomatic, isolated hypercholesterolaemia and if statin treatment could influence this cytokine.

    Methods: The investigation was designed as a cross sectional study followed by a single, blind, treatment study of patients receiving pravastatin 80 mg/day for 8 weeks. The study included 23 patients with severe hypercholesterolaemia (LDL>5.2 mmol/L) and 39 normocholesterolaemic controls. Blood samples were obtained from patients and controls at baseline and from patients at end of the study and analysed for lipoproteins and inflammatory mediators: MCP‐1, high‐sensitivity C‐reactive protein (HS‐CRP). Isolated peripheral mononuclear cells were analysed for CCR‐2 gene expression.

    Results: Mean plasma LDL‐C was significantly higher in patients than in controls. No difference in plasma MCP‐1 levels or CCR‐2 gene expression was seen between the groups at baseline, nor were there any differences in plasma concentrations of CRP. After treatment with pravastatin, LDL‐C decreased by 31%. Treatment did not significantly affect the levels of MCP‐1 or CCR‐2 gene expression, nor was CRP affected by treatment with pravastatin.

    Conclusions: Our study does not support the view that MCP‐1 plasma levels and CCR‐2 gene expression in circulating monocytes are directly responsible for the monocyte recruitment into the arterial intima in patients with severe asymptomatic hypercholesterolaemia. In addition, the inflammatory response of a high concentration of LDL‐C in isolated asymptomatic hypercholesterolaemia is minute.

  • 4.
    Li, Wei
    et al.
    Linköping University, Faculty of Health Sciences. Linköping University, Department of Neuroscience and Locomotion, Pathology.
    Hellsten, Anna
    Linköping University, Department of Biomedicine and Surgery.
    Jacobsson, Leif
    Linköping University, Faculty of Health Sciences. Linköping University, Department of Medicine and Care, Pharmacology.
    Blomqvist, Henrik
    Linköping University, Faculty of Health Sciences. Linköping University, Department of Medicine and Care, Internal Medicine.
    Olsson, Anders
    Linköping University, Faculty of Health Sciences. Linköping University, Department of Medicine and Care, Internal Medicine. Östergötlands Läns Landsting, Centre for Medicine, Department of Endocrinology and Gastroenterology UHL.
    Yuan, Xi Ming
    Linköping University, Faculty of Health Sciences. Linköping University, Department of Neuroscience and Locomotion, Pathology.
    Alpha-tocopherol and astaxanthin decrease macrophage infiltration, apoptosis and vulnerability in atheroma of hyperlipidaemic rabbits2004In: Journal of Molecular and Cellular Cardiology, ISSN 0022-2828, E-ISSN 1095-8584, Vol. 37, no 5, p. 969-978Article in journal (Refereed)
    Abstract [en]

    The composition of atherosclerotic plaques, not just macroscopical lesion size, has been implicated in their susceptibility to rupture and the risk of thrombus formation. By focusing on the quality of lipids, macrophages, apoptosis, collagen, metalloproteinase expression and plaque integrity, we evaluated the possible anti-atherosclerotic effect of the antioxidants α-tocopherol and astaxanthin in Watanabe heritable hyperlipidemic (WHHL) rabbits. Thirty-one WHHL rabbits were divided into three groups and were fed a standard diet, as controls (N =10), or a standard diet with the addition of 500 mg α-tocopherol per kg feed (N =11) or 100 mg astaxanthin per kg feed (N =10) for 24 weeks. We found that both antioxidants, particularly astaxanthin, significantly decreased macrophage infiltration in the plaques although they did not affect lipid accumulation. All lesions in the astaxanthin-treated rabbits were classified as early plaques according to the distribution of collagen and smooth muscle cells. Both antioxidants also improved plaque stability and significantly diminished apoptosis, which mainly occurred in macrophages, matrix metalloproteinase three expressions and plaque ruptures. Although neither antioxidant altered the positive correlations between the lesion size and lipid accumulation, the lesion size and apoptosis were only positively correlated in the control group. Astaxanthin and α-tocopherol may improve plaque stability by decreasing macrophage infiltration and apoptosis in this atherosclerotic setting. Apoptosis reduction by α-tocopherol and astaxanthin may be a new anti-atherogenic property of these antioxidants. © 2004 Elsevier Ltd. All rights reserved.

  • 5.
    Olsson, Anders
    et al.
    Linköping University, Faculty of Health Sciences. Linköping University, Department of Medicine and Care, Internal Medicine. Östergötlands Läns Landsting, Centre for Medicine, Department of Endocrinology and Gastroenterology UHL.
    Cherfan, P
    Blomqvist, Henrik
    Linköping University, Faculty of Health Sciences. Linköping University, Department of Medicine and Care, Internal Medicine.
    Jonasson, Lena
    Linköping University, Faculty of Health Sciences. Linköping University, Department of Medicine and Care, Cardiology. Östergötlands Läns Landsting, Heart Centre, Department of Cardiology.
    Serum adiponectin - its association with inflammation and statin treatment2005In: EAS Congress,2005, 2005Conference paper (Other academic)
1 - 5 of 5
CiteExportLink to result list
Permanent link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf